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Nicotinic acid: an old drug with a promising future
ET Bodor and S Offermanns
Institute of Pharmacology, University of Heidelberg, Im Neuenheimer Feld, Heidelberg, Germany
Nicotinic acid has been used for decades to treat dyslipidaemic states. In particular its ability to raise the plasma HDL
cholesterol concentration has led to an increased interest in its pharmacological potential. The clinical use of nicotinic acid is
somewhat limited due to several harmless but unpleasant side effects, most notably a cutaneous flushing phenomenon. With
the recent discovery of a nicotinic acid receptor, it has become possible to better understand the mechanisms underlying the
metabolic and vascular effects of nicotinic acid. Based on these new insights into the action of nicotinic acid, novel strategies
are currently under development to maximize the pharmacological potential of this drug. The generation of both flush-
reducing co-medications of nicotinic acid and novel drugs targeting the nicotinic acid receptor will provide future therapeutic
options for the treatment of dyslipidaemic disorders.
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Introduction
The reduction of the plasma levels of cholesterol associated
with proatherogenic ‘low-density lipoprotein’ (LDL) particles
is one of the most important therapeutic measures to reduce
cardiovascular morbidity and mortality. LDL cholesterol
plasma levels can be pushed far below 100mg per 100ml
by the inhibition of cholesterol synthesis, using HMG-CoA-
reductase inhibitors (statins) alone or in combination with
cholesterol-resorption inhibitors. Despite this very effica-
cious treatment, clinical studies have shown that even an
aggressive reduction in LDL cholesterol reduces the occur-
rence of cardiovascular events by only 25–40% (Mahley and
Bersot, 2006). This result is due to the fact that high LDL
cholesterol levels are not the only risk factor for cardiovas-
cular diseases. In addition to genetic factors, hypertension,
age and cigarette smoking, low ‘high-density lipoprotein’
(HDL) cholesterol levels are also an independent risk factor
(Gordon et al., 1977; Castelli et al., 1986). Currently, HDL
cholesterol levels of p40–45mg per 100ml are regarded as a
risk factor for coronary heart disease, whereas levels 460mg
per 100ml are considered protective (Grundy et al., 2004).
The development of new strategies to elevate HDL cholesterol
plasma levels has therefore been intensified in recent years
(Chapman, 2006; Rader, 2006). One of the most promising
new approaches to raise HDL cholesterol levels, inhibition of
the cholesterol ester transfer protein (CETP) (Le Goff et al.,
2004), has recently suffered a setback when the CETP
inhibitor torcetrapib failed in the phase III trials (Nissen
et al., 2007). Currently, the oldest lipid-modifying drug,
nicotinic acid (niacin), is attracting renewed attention as it
has the strongest HDL cholesterol-elevating effect among the
drugs currently approved for the treatment of lipid disorders
(Table 1). In this review, we will summarize the pharmacology
of nicotinic acid with particular focus on recent findings that
have elucidated the mechanisms underlying some of the
effects of nicotinic acid.
Clinical use of nicotinic acid
Nicotinic acid has profound and unique effects on lipid
metabolism and is thus referred to as a ‘broad-spectrum lipid
drug’ (Carlson, 2005). In addition to elevating HDL choles-
terol (Parsons and Flinn, 1959; Shepherd et al., 1979) as well
as decreasing both LDL and total cholesterol (Altschul et al.,
1955; Carlson et al., 1977), nicotinic acid also induces a
decrease in the concentrations of both ‘very-low-density
lipoproteins’ (VLDL) and plasma triglyceride (TG) (Table 1;
Carlson et al., 1989). The plasma concentration of lipo-
protein Lp(a), which has been suggested to play a role as an
independent risk factor for coronary heart disease, is also
decreased by nicotinic acid (Carlson et al., 1989; Berglund
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www.brjpharmacol.organd Ramakrishnan, 2004). Soon after the initial discovery of
the lipid-modifying effect of high doses of nicotinic acid
(Altschul et al., 1955), the water-soluble vitamin nicotinic
acid was introduced into clinical therapy as the first lipid-
modifying drug. In the Coronary drug project, conducted
from 1966 to 1975, nicotinic acid administered as mono-
therapy at 3gday
 1 was shown to lead to an efficient
secondary prevention of myocardial infarction (Table 2)
(Coronary Drug Project Research Group, 1975). A follow-up
study of the Coronary Drug project revealed that nicotinic
acid also reduced the mortality of patients who had been
treated with nicotinic acid (Canner et al., 1986). The
Stockholm ischaemic heart disease secondary prevention
study came to similar findings (Carlson and Rosenhamer,
1988). With the introduction of cholesterol synthesis
inhibitors (statins) in the therapy of hypercholesterolaemia
during the late 1980s, interest in the therapeutic potential of
nicotinic acid decreased. However, in recent years, several
clinical studies have been conducted to test whether
nicotinic acid provides a benefit to patients who are
receiving treatment with statins but still display low HDL
cholesterol levels. Both the HDL Atherosclerosis Treatment
Study and the Arterial Biology for the Investigation of the
Treatment Effects of Reducing Cholesterol study indicate
that patients with low HDL cholesterol levels benefit from a
treatment with nicotinic acid in addition to statins (Brown
et al., 2001; Taylor et al., 2004). However, both studies are
relatively small and have some limitations, including
the lack of an ideally designed control group in HDL
Atherosclerosis Treatment Study or the evaluation of the
intima-media thickness of the carotid artery as a surrogate
parameter for the development of clinically relevant athero-
sclerosis in the Arterial Biology for the Investigation of the
Treatment Effects of Reducing Cholesterol study. In any case,
there is good evidence supporting a therapeutic benefit of
nicotinic acid (Brown, 2005), and randomized long-term
studies to evaluate the effect of nicotinic acid in addition to
statins in patients with low HDL cholesterol levels and
increased cardiovascular risk have recently been initiated
(Brown, 2006).
Nicotinic acid effects on lipid metabolism
The most rapid effect of nicotinic acid on lipid metabolism is
a decrease in plasma levels of free fatty acid , which can be
observed within minutes upon administration of the drug.
After a few hours, the plasma VLDL and TG levels are
reduced, whereas the LDL and HDL cholesterol levels are
changed only after several days of treatment (Carlson et al.,
1968a). Soon after the discovery of the cholesterol-lowering
effect of nicotinic acid, the still-prevailing hypothesis was
formulated that the effects of nicotinic acid on LDL and HDL
cholesterol levels are the result of a very rapid antilipolytic
effect on adipocytes (Figure 1). This was based on studies
in vivo as well as in vitro using isolated adipocytes (Carlson
and Oro ¨, 1962; Carlson, 1963; Butcher et al., 1968). The rapid
decrease in plasma free fatty acid levels due to the
antilipolytic effect of nicotinic acid is believed to result in
reduced supply of substrate for the hepatic synthesis of TGs
Table 2 Clinical trials, which have evaluated the effect of nicotinic acid in the prevention of cardiovascular diseases
Study Method Placebo Nicotinic acid P-value
Coronary Drug Project (1975) 8341 patients after myocardial infarction
5 years, 3gday
 1 myocardial infarctiontotal mortality
12.2%
20.9%
8.9%
21.2%
o0.05
NS
Canner et al. (1986) Coronary Drug Project follow-up after 15 years
Total mortality
58.2% 52% o0.005
Carlson and Rosenhammer (1988) 276 patients after myocardial infarction nicotinic
acidþclofibrate
Total mortality
29.7% 21.8% o0.05
HATS
a, (58) 160 patients with coronary heart disease and low HDL
cholesterol (males o35mg per 100ml; females o40mg per
100ml), 3 years nicotinic acid
(2–4gday
 1) þ simvastatin (10–20mgday
 1)
Cardiovascular events
NT
b 3%
ARBITER 2
c, Taylor et al. (2004) 167 patients with coronary heart disease and low HDL
cholesterol (o45mg per 100ml), 1 year nicotinic acid
(1gday
 1)þsimvastatin
Increase in intima-media thickness of carotid artery
0.044mm 0.014mm o0.08
Abbreviations: HDL, high-density lipoprotein; NS, not significant; NT, not tested.
aHDL Atherosclerosis Treatment Study (Brown et al., 2001).
bA placebo group (simvastatin only) was not studied in the HATS trial. The clinical and angiographic benefit of a combination treatment with simvastatin and
nicotinic acid was, however, far higher than would have been expected with a simvastatin only treatment.
cArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (Taylor et al., 2004).
Table 1 Effect of various lipid-modifying drugs
LDL-C HDL-C TG
Statins 20–55% k 5–10% m 7–30% k
Fibrates 5–20% k 10–20% m 20–50% k
Nicotinic acid 5–25% k 15–35% m 20–50% k
Anion exchange resins 10–20% k 3–5% m —
Ezetemibe 15–20% k (m)( k)
Abbreviations: HDL-C, high-density lipoprotein cholesterol; LCL-D, low-density
lipoprotein cholesterol; TG, triglycerides.
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reduced formation of LDL particles (Figure 1). Recent studies
in a hepatoblastoma cell line have suggested that nicotinic
acid may have direct effects on hepatocytes, and may
decrease hepatic VLDL and TG synthesis by the inhibition
of diacylglycerol acyl transferase 2 and accelerating the
intracellular degradation of apoprotein B (Jin et al., 1999;
Ganji et al., 2004). However, these in vitro effects were
observed only at nicotinic acid concentrations considerably
higher than the plasma concentrations required for the
in vivo effects on the plasma levels of TG and VLDL.
It is also not clear how nicotinic acid induces an increase
in HDL cholesterol levels. The most plausible hypothesis is
based on the well-established inverse correlation between TG
levels and plasma HDL cholesterol concentrations (Szapary
and Rader, 2001), which is primarily due to the exchange of
TGs and cholesterol esters between apoprotein B-containing
lipoproteins (especially VLDL and LDL) and HDL, which is
mediated by CETP. According to this concept, the decrease in
TG concentration in VLDL and LDL particles in response to
nicotinic acid results in a reduced exchange of cholesterol
esters and TGs and a subsequent increase in the plasma
concentration of HDL cholesterol (Figure 1). This hypothesis
is supported by the fact that inhibition of CETP has very
similar effects to nicotinic acid treatment on the plasma
concentration of HDL , in that both cause an elevation of the
HDL2 fraction (Le Goff et al., 2004). Interestingly, in mice,
which do not express CETP, the relatively high basal HDL
cholesterol levels are rather decreased by nicotinic acid.
Yet transgenic mice expressing the human CETP gene
show lowered levels of basal HDL cholesterol and respond
with an increase in HDL cholesterol levels to nicotinic acid
treatment (Hernandez et al., 2007). However, it has also been
proposed that nicotinic acid increases plasma HDL levels
by decreasing the catabolism of HDL (Blum et al., 1977;
Shepherd et al., 1979). In addition, millimolar concentra-
tions of nicotinic acid have been shown to decrease the
uptake of HDL-apoprotein A-I by a hepatoma cell line in vitro
(Jin et al., 1997).
Recent studies have also suggested that some of the
beneficial long-term effects of nicotinic acid may, at least
in part, involve macrophages. Nicotinic acid has been shown
to increase the expression of peroxisome proliferator-
activated receptor-g and to enhance peroxisome prolifera-
tor-activated receptor-g transcriptional activity in macro-
phages (Rubic et al., 2004; Knowles et al., 2006). However,
the mechanism underlying this effect and its pharmacologi-
cal relevance are still unclear.
The nicotinic acid receptor
Over 25 years ago, a nicotinic acid receptor on adipocytes
was postulated based on the observation that the strong and
rapid antilipolytic effects of nicotinic acid are mediated by a
Gi-dependent inhibition of adenylyl cyclase (Aktories et al.,
1980). Following the demonstration of specific binding sites
for nicotinic acid on plasma membranes of adipocytes and
spleen cells (Lorenzen et al., 2001), the receptor for nicotinic
acid was identified (Soga et al., 2003; Tunaru et al., 2003;
Wise et al., 2003) as the orphan receptor GPR109A, also
referred to as HM74A in humans and protein up-regulated in
macrophages by interferone-g (PUMA-G) in mice. In addi-
tion to brown and white adipose tissue, GPR109A is also
expressed in various immune cells, including monocytes,
macrophages, dendritic cells and neutrophils (Yousefi et al.,
2000; Schaub et al., 2001; Soga et al., 2003; Tunaru et al.,
2003; Wise et al., 2003; Maciejewski-Lenoir et al., 2006).
GPR109A is coupled to Gi type G proteins, and its activation
by nicotinic acid results in a Gi-mediated inhibition of
adenylyl cyclase, resulting in a decrease in intracellular cyclic
AMP levels. This cyclic nucleotide is the principal mediator
of adipocyte lipolysis (Figure 1). Lipolysis is increased when
cAMP levels are elevated due to increased adenylyl cyclase
activity, for example, by b-adrenergic receptor activation or
by decreased phosphodiesterase-mediated cAMP degradation
(Duncan et al., 2007). Thus, the nicotinic acid-induced,
GPR109A-mediated adenylyl cyclase inhibition counteracts
the prolipolytic effects of elevated intracellular cAMP levels.
The relevance of the nicotinic acid receptor GPR109A as a
mediator of the pharmacological effects of nicotinic acid
could be demonstrated in mice lacking GPR109A. In these
animals, the nicotinic acid-induced antilipolytic effects on
fat cells as well as the decrease in the plasma levels of free
fatty acid and TG in response to nicotinic acid are abrogated
(Tunaru et al., 2003). Thus, strong evidence exists that at
Figure 1 Mechanisms of nicotinic acid-induced changes in lipid metabolism. ATGL, adipocyte-triacylglycerol-lipase; CETP, cholesterol ester
transfer protein; FFA, free fatty acid; HSL, hormone-sensitive lipase; PKA, protein kinase A; TG, triglyceride.
Nicotinic acid
ET Bodor and S Offermanns S70
British Journal of Pharmacology (2008) 153 S68–S75least the initial steps of the nicotinic acid-induced changes
in lipid metabolism are mediated by GPR109A.
The closest homologue of the human GPR109A is
GPR109B, which is not found in rodents and clearly
represents the result of a relatively recent gene duplication
(Zellner et al., 2005). Interestingly, nicotinic acid and related
drugs with comparable pharmacological effects, such as
acipimox (Fuccella et al., 1980; Tornvall and Walldius,
1991), bind to GPR109A but not to GPR109B (Soga et al.,
2003; Tunaru et al., 2003; Wise et al., 2003). However, the
furan carboxylic acid acifran is able to activate both receptors
(Wise et al., 2003; Figure 2). Several heterocyclic small
molecules have been shown to act as selective agonists of
GPR109A, however, none of them appear to surpass
nicotinic acid with regard to potency (Wang and Fotsch,
2006; Gharbaoui et al., 2007; Jung et al., 2007; Soudijn et al.,
2007). Recently, a variety of 1- and 2-substituted benzotria-
zole-5-carboxylic acids, such as 1-isopropyl-benzotriazole-5-
carboxylic acid, have been reported to be selective and
relatively potent agonists at GPR109B (Semple et al., 2006).
Nicotinamide, which shares with nicotinic acid its function
as a vitamin but has no pharmacological effects comparable
to nicotinic acid, does not activate any of the receptors
(Soga et al., 2003; Tunaru et al., 2003; Wise et al., 2003).
Under physiological conditions, nicotinic acid concentra-
tions in the plasma are relatively low, thus nicotinic acid is
unlikely to be the endogenous ligand for GPR109A. Recently,
the endogenous ketone body b-hydroxybutyrate was
shown to selectively activate GPR109A (Taggart et al.,
2005). The potency of b-hydroxybutyrate is relatively low
(EC50¼750mM) yet does fall within its physiological con-
centrations in the plasma, which range from 50 to 400mM
under normal conditions to as high as 6–8mM under
starvation conditions. Thus, GPR109A appears to mediate
the known antilipolytic effect of high concentrations of
b-hydroxybutyrate, a negative feedback mechanism that
may contribute to metabolic homoeostasis during starvation
(Senior and Loridan, 1968).
All known agonists of the nicotinic acid receptor GPR109A
have in common that they are relatively small molecules,
which contain a carboxylic acid moiety. Intensive mutagen-
esis studies of the nicotinic acid receptor suggest that the
binding pocket is formed by transmembrane helices 2, 3
and 7 (Figure 3), and that an arginine residue (Arg111) in the
transmembrane helix 3 represents the anchor point for
the carboxylic acid group of nicotinic acid and other
receptor agonists (Tunaru et al., 2005). Other important
contacts of the pyridine ring of nicotinic acid with the
Figure 3 Model of GPR109A-binding nicotinic acid. (left panel) View on the extracellular site of the receptor, which binds nicotinic acid
(yellow) in its binding pocket from transmembrane helices 2, 3 and 7. (right panel) Model of the most important interactions of nicotinic acid
with amino-acid residues of the receptor. TMH, transmembrane helix; ECL, extracellular loop. The coordinates used to draw the model were
generated by J La ¨ttich and G Krause (FMP, Berlin) (Tunaru et al., 2005).
Figure 2 Properties (a) and structures (b) of various ligands of
GPR109A and GPR109B. EC50 values were determined by measuring
binding of GTPgS to membranes or by measuring adenylyl cyclase
inhibition. 1-IPBT-5-CA, 1-isopropyl-benzotriazole-5 carboxylic acid.
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junction of transmembrane helix 2, the extracellular loop 1
and the transmembrane helix 7. A serine residue (Ser178) in
the extracellular loop 2 is essential for binding nicotinic acid to
the receptor and may mediate the interaction with the
nitrogen of the pyridine ring (Tunaru et al., 2005).
Pharmacokinetics
After oral administration, nicotinic acid is absorbed rapidly
and maximal plasma concentrations are reached after
30–60min. The plasma half-life after administration of 1g
nicotinic acid is around 1h (Carlson et al., 1968b; Svedmyr
and Harthon, 1970). Nicotinic acid is in part metabolized by
the liver and in part excreted unchanged by the kidney. At
low doses, a considerable fraction of nicotinic acid is
metabolized via nicotinamide to N-methyl-nicotinamide,
which is then further metabolized to N-methyl-2-pyridon-5-
carboxamide and N-methyl-4-pyridon-5-carboxamide and
are then renally excreted (Stern et al., 1992). At intermediate
and high pharmacological doses (1–3g), an increasing
fraction of nicotinic acid is conjugated with glycin and then
excreted as nicotinuric acid by the kidney. With increasing
doses, the direct renal excretion of nicotinic acid predomi-
nates (Petrack et al., 1966).
The nicotinic acid-induced flushing response
Nicotinic acid, when given at pharmacological doses, has
several unwanted yet harmless effects. The most common
and most prominent unwanted effect of nicotinic acid is a
cutaneous vasodilation, most prominently in the upper half
of the body and in the face, which lasts for 1–2h after an oral
dose of nicotinic acid (Goldsmith and Cordill, 1943). This
cutaneous reaction, called flushing, is relatively unpleasant
and therefore negatively influences patients’ compliance.
This dilatory effect on dermal blood vessels is also the basis
of the local effects of some dermatic formulations of
nicotinic acid esters, including propyl-, benzyl- or methyl-
nicotinate. In contrast to the nicotinic acid effects on lipid
metabolism that are stable over long periods of treatment
with nicotinic acid, the nicotinic acid-induced flushing
response is subject to some tolerance, resulting in a reduced
flushing response in the course of weeks (Stern et al., 1991).
Recent studies in GPR109A-deficient mice have shown
that the nicotinic acid-induced flushing response is
mediated by the nicotinic acid receptor (Benyo ´ et al.,
2005). The failure of GPR109A-deficient mice to respond to
nicotinic acid with cutaneous vasodilation can be rescued
by transplanting wild-type bone marrow to irradiated
GPR109A-deficient animals (Benyo ´ et al., 2005), strongly
suggesting that the receptor on bone marrow-derived cells
and not on adipocytes mediates the flushing response. This
finding, along with the fact that topical application of
skin-permeable nicotinic acid esters results in a cutaneous
reaction indistinguishable from the response induced by
systemic application of nicotinic acid, suggests that the nico-
tinic acid-induced flushing response is a local phenomenon
induced by activation of the receptor on dermal or epidermal
immune cells. Strong evidence has been provided that
epidermal Langerhans cells are critically involved in the
nicotinic acid-induced flushing response (Benyo ´ et al., 2006;
Maciejewski-Lenoir et al., 2006). This is based on the
observation that Langerhans cells express GPR109A and
respond to nicotinic acid with an increase in intracellular
Ca
2þ as well as the formation of prostanoids (Maciejewski-
Lenoir et al., 2006). In addition, nicotinic acid does not
induce a flushing response in mice, which are depleted of
Langerhans cells (Benyo ´ et al., 2006).
It has long been known that treatment with COX
inhibitors can reduce the nicotinic acid-induced flushing
response while having no effect on the beneficial effects of
nicotinic acid (Andersson et al., 1977; Eklund et al., 1979;
Kaijser et al., 1979). Indeed, prostanoids, especially prosta-
glandin D2 (PGD2) or their metabolites, have been shown to
be produced after administration of nicotinic acid (Morrow
et al., 1989; Stern et al., 1991). Pharmacological and genetic
evidence from studies in mice clearly indicates that the
nicotinic acid-induced flushing response is mediated by
PGD2 and prostaglandin E2, which dilate dermal blood
vessels via the activation of DP1 and EP2/EP4 receptors
(Benyo ´ et al., 2005; Cheng et al., 2006). From these and other
data, a model of the nicotinic acid-induced flushing response
has emerged. Nicotinic acid induces an increase in intra-
cellular Ca
2þ via activation of GPR109A on epidermal
Langerhans cells. This results in the activation of a Ca
2þ-
sensitive phospholipase A2 and the formation of arachidonic
acid, which is further metabolized to PGD2 and prostaglan-
din E2. Both prostanoids are then able to induce the dilation
of blood vessels in the upper layer of the dermis by activation
of their Gs-coupled receptors (Figure 4).
Several strategies have been proposed to reduce nicotinic
acid-induced flushing. It is, for example, generally recom-
mended to gradually increase the daily dose over a period of
1–4 months. As the onset of flushing rapidly follows the
increase in nicotinic acid plasma levels after oral ingestion,
slow-release formulations of nicotinic acid have been
generated, which result in a delay and decrease of the peak
plasma concentration of nicotinic acid and hence lead to
fewer flushing events (Knopp et al., 1998). The fact that the
antilipolytic effects of nicotinic acid as well as the flushing
response are mediated by GPR109A makes it difficult to
Figure 4 Proposed mechanism of the nicotinic acid-induced
flushing response. AA, arachidonic acid; COX-1, cyclooxygenase-1;
PGD2, prostaglandin D2; PGE2, prostaglandin E2; PLA2, phospho-
lipase A2.
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agonists of GPR109A. However, recent data indicate that
partial agonists of GPR109A may have a reduced efficacy
with regard to the induction of flushing while retaining
mainly their antilipolytic activity (Richman et al., 2007). An
alternative approach to reduce the unwanted flushing
response could be the co-application of drugs that interfere
with the downstream mechanisms of the nicotinic acid-
induced flushing response. COX inhibitors including aspirin
have been shown to reduce the flush response to nicotinic
acid (Oberwittler and Baccara-Dinet, 2006), however, their
side effects preclude long-term administration. Based on the
recent elucidation of the mechanisms underlying nicotinic
acid-induced flushing (see above), the specific inhibition of
PGD2 and prostaglandin E2 formation or action appears to be
a very promising strategy. In fact, it has recently been shown
that the DP1 receptor antagonist laropiprant (MK-0524)
inhibits the nicotinic acid-induced flushing response in
humans (Cheng et al., 2006; Lai et al., 2007).
Other unwanted effects
In some cases, the application of nicotinic acid has been
reported to result in gastrointestinal effects, such as dyspepsia,
diarrhoea or nausea. The mechanisms of these unwanted
effects are unclear. Increases in plasma transaminase activity
indicating a hepatotoxic effect have been reported in patients
treated with nicotinic acid. This effect appears to be more
frequently observed when sustained-release formulations of
nicotinic acid are given, suggesting that an increased hepatic
metabolism underlies this hepatotoxic effect (Etchason et al.,
1991; Dalton and Berry, 1992). Patients predisposed to
hyperuricaemia and gout have been reported to display a
tendency towards elevated plasma levels of uric acid in
response to nicotinic acid, which is likely due to a competition
of nicotinic acid and uric acid for the same renal excretion
mechanism (Anzai et al., 2007).
Patients suffering from type II diabetes mellitus often have
dyslipidaemic changes characterized by an increase in TG
levels as well as a decrease in HDL cholesterol levels. Given the
characteristic profile of the pharmacological effects of nico-
tinic acid on lipid metabolism, nicotinic acid should counter-
act the dyslipidaemic changes in diabetic patients. However,
several reports have been published indicating that nicotinic
acid increases insulin resistance (Garg and Grundy, 1990;
McCulloch et al., 1991). The mechanisms of this unwanted
effect remain unclear. Recent analyses have, however, indi-
cated that the risk–benefit ratio of nicotinic acid therapy in
diabetic patients was similar to that of patient with normal
glucose tolerance (Grundy et al., 2002; Canner et al., 2005).
A final assessment of the effects of long-term nicotinic acid
treatment in patients with diabetes mellitus is currently not
possible, and rigid glycemic control should be ensured in
diabetic or prediabetic patients treated with nicotinic acid.
Conclusions
Nearly 50 years ago, nicotinic acid was introduced into
clinical practice as the first lipid-modifying drug. Its status
among the growing number of antidyslipidaemic drugs has
changed over the years. With the increased awareness of the
role low HDL cholesterol levels play as a risk factor for
cardiovascular diseases, the strong HDL cholesterol-elevating
effect of nicotinic acid has resulted in an increased interest in
the pharmacological properties of this drug. The clinical use
of nicotinic acid, however, has been hampered by harmless
but unpleasant side effects, primarily the flushing phenom-
enon. With the recent discovery of a specific receptor for
nicotinic acid, the molecular mechanisms underlying the
pharmacological effects of nicotinic acid have become
clearer. In the upcoming years, it will be important to fully
understand which of the effects are mediated by the receptor
and which are not. Research on the mechanisms of nicotinic
acid has already strongly influenced the development of new
drugs for the treatment of dyslipidaemic states. New agents
acting via the nicotinic acid receptor are currently being
developed in various pharmaceutical companies. In addi-
tion, new co-medications, which aim to suppress the
nicotinic acid-induced flushing response without affecting
the wanted effects of nicotinic acid, are being tested.
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